IMAB I-MAB ADRs

I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$3.04  -0.07 (-2.10%)
As of 03/27/2023 13:02:02 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  01/17/2020
Outstanding shares:  83,098,842
Average volume:  278,322
Market cap:   $268,409,260
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BKRRKY7

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%